ArticleScience translational medicine2018
T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 198 papers.
0numbers the graph read from it
0cells of the map it votes in
198citing papers in PubMed
14.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
198 citing papers in PubMed, 293 citations in OpenAlex.
- Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer.Cancer research communications · 2023Trial
- Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial.Journal for immunotherapy of cancer · 2020Trial
- Comparison of Human Melanoma Single Cell Profiles to Evolutionary Medicine Model Xiphophorus Provides Insights in Disease Control.Pigment cell & melanoma research · 2026Article
- Explainable machine learning identifies features and thresholds predictive of immunotherapy response.Scientific reports · 2026Article
- Uncovering the Intricate and Heterogeneous Cellular Microenvironment of Cutaneous Melanoma.Medicina (Kaunas, Lithuania) · 2026Review
- The double-edged sword role of tumor-associated macrophages: preventing or causing resistance to immunotherapy.Journal of experimental & clinical cancer research : CR · 2026Review
- Causal modeling reveals cell-cell communication dynamics in the tumor microenvironment during anti-PD-1 therapy in breast cancer patients.Briefings in bioinformatics · 2026Article
- Colorectal cancer-derived osteopontin rewires macrophages into a pro-metastatic M2 state via the PI3K/AKT/CSF1-CSF1R axis.Cell death discovery · 2026Article
- TAM-targeted nanomedicine in cancer: biological basis, therapeutic strategies, and translational perspectives.Theranostics · 2026Review
- Single-cell multiomics reveals macrophage-derived IL-23 and CXCL9/10 drive pathogenic IFNGJournal for immunotherapy of cancer · 2025Article
- Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure.ESMO open · 2025Review
- 2240 nm NIR-IV Photodynamic Therapy Can Reverse Ineffective Anti-OX40 Cancer Immunotherapy to Become Effective.ACS nano · 2025Article
- Dendritic cell progenitors engineered to express extracellular-vesicle-internalizing receptors enhance cancer immunotherapy in mouse models.Nature communications · 2025Article
- Uncovering Cellular Interactome Drivers of Immune Checkpoint Inhibitor Response in Advanced Melanoma Patients.Cellular and molecular bioengineering · 2025Article
- Macrophage-centered therapy strategies: A promising weapon in cancer immunotherapy.Asian journal of pharmaceutical sciences · 2025Review
- Targeting CSF-1 signaling between tumor cells and macrophages at TMEM doorways inhibits breast cancer dissemination.Oncogene · 2025Article
- Scaffold-Free Functional Deconvolution Identifies Clinically Relevant Metastatic Melanoma EV Biomarkers.Cancers · 2025Article
- Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy.Cancer cell · 2025Review
- Myeloid cells: key players in tumor microenvironments.Frontiers of medicine · 2025Review
- Immune Modulation and Immunotherapy in Solid Tumors: Mechanisms of Resistance and Potential Therapeutic Strategies.International journal of molecular sciences · 2025Review
138 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 2 countries.
Natalie J NeubertLudwig Cancer Research Center and Department of Oncology, University of Lausanne (UNIL), CH-1066 Epalinges, Switzerland.ORCID 0000-0002-8860-5236
Martina SchmittnaegelSwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.ORCID 0000-0002-8037-5309
Natacha BordryLudwig Cancer Research Center and Department of Oncology, University of Lausanne (UNIL), CH-1066 Epalinges, Switzerland.ORCID 0000-0002-3523-438X
Sina NassiriSwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.
Noémie WaldLudwig Cancer Research Center and Department of Oncology, University of Lausanne (UNIL), CH-1066 Epalinges, Switzerland.
Christophe MartignierLudwig Cancer Research Center and Department of Oncology, University of Lausanne (UNIL), CH-1066 Epalinges, Switzerland.ORCID 0000-0001-6476-1659
Laure TilléLudwig Cancer Research Center and Department of Oncology, University of Lausanne (UNIL), CH-1066 Epalinges, Switzerland.ORCID 0000-0001-8163-0837
Krisztian HomicskoLudwig Cancer Research Center and Department of Oncology, University of Lausanne (UNIL), CH-1066 Epalinges, Switzerland.
William DamskyDepartments of Dermatology and Immunobiology, Yale School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0003-0975-4071
Hélène Maby-El HajjamiLudwig Cancer Research Center and Department of Oncology, University of Lausanne (UNIL), CH-1066 Epalinges, Switzerland.ORCID 0000-0002-5786-5991
Irina KlamanRoche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Nonnenwald 2, D-82377 Penzberg, Germany.
Esther DanenbergCenter of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), CH-1005 Lausanne, Switzerland.
Kalliopi IoannidouLudwig Cancer Research Center and Department of Oncology, University of Lausanne (UNIL), CH-1066 Epalinges, Switzerland.ORCID 0000-0001-9097-4199
Lana KandalaftCenter of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), CH-1005 Lausanne, Switzerland.ORCID 0000-0002-1575-6674
George CoukosLudwig Cancer Research Center and Department of Oncology, University of Lausanne (UNIL), CH-1066 Epalinges, Switzerland.ORCID 0000-0001-8813-7367
Sabine HovesRoche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Nonnenwald 2, D-82377 Penzberg, Germany.ORCID 0000-0002-4953-7234
Carola H RiesRoche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Nonnenwald 2, D-82377 Penzberg, Germany.ORCID 0000-0002-1855-8745
Silvia A Fuertes MarracoLudwig Cancer Research Center and Department of Oncology, University of Lausanne (UNIL), CH-1066 Epalinges, Switzerland.
Periklis G FoukasCenter of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), CH-1005 Lausanne, Switzerland.
Michele De PalmaSwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland. michele.depalma@epfl.ch doc@dspeiser.ch.ORCID 0000-0001-9128-5459
Daniel E SpeiserLudwig Cancer Research Center and Department of Oncology, University of Lausanne (UNIL), CH-1066 Epalinges, Switzerland. michele.depalma@epfl.ch doc@dspeiser.ch.ORCID 0000-0003-2031-3250
Ludwig Cancer Research · CHUniversity Hospital of Lausanne · CHÉcole Polytechnique Fédérale de Lausanne · CHRoche (Switzerland) · CHYale University · US
Funding
Training in Investigative DermatologyT32AR007016 · NIAMS · YALE UNIVERSITY · PI KEITH A CHOATE, MICHAEL GIRARDI · 1986 to 2026
$7.8MNIAMS NIH HHS T32 AR007016
Abstract
Colony-stimulating factor 1 (CSF1) is a key regulator of monocyte/macrophage differentiation that sustains the protumorigenic functions of tumor-associated macrophages (TAMs). We show that CSF1 is expressed in human melanoma, and patients with metastatic melanoma have increased CSF1 in blood compared to healthy subjects. In tumors, CSF1 expression correlated with the abundance of CD8
Indexed as
AnimalsAntigens, CDAntigens, Differentiation, MyelomonocyticCD163 AntigenCD8-Positive T-LymphocytesCell DifferentiationCell Line, TumorHumansMacrophage Colony-Stimulating FactorMacrophagesMelanomaMiceProto-Oncogene Proteins B-rafReceptors, Cell SurfaceSignal TransductionAntigens, CDAntigens, Differentiation, MyelomonocyticBRAF protein, humanCD163 AntigenMacrophage Colony-Stimulating FactorProto-Oncogene Proteins B-rafReceptors, Cell Surface
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.